2019 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Prevalence of Patients with Limited Treatment Options

20%

18%

16%

14%

12%

10%

514LTO of6,857

8%

151LTO of8,348

6% Percentage LTO

4%

107LTO of13,350

2%

0%

2000 2002 2004 2006 2008 2010 2012 2014 2016

Year

Crane et al, IAS2019

Slide61of65FromMSSaag,MDatNewOrleans, LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICALCONFERENCE, IAS  USA.

Virologic Success in Those with or without LTO

Slide62of65FromMSSaag,MDatNewOrleans, LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICALCONFERENCE, IAS  USA.

Crane et al, IAS2019

Discussion

 Confirm the virologic failure  Explore all prior regimens and resistance tests  Identify 2 fully active drugs (if possible) – Use Dolutegravir (50 mg) twice daily – Some form of Tenofovir (as long as no K65R) – Boosted darunavir – 3TC or FTC (despite resistance)  Ibalizumab  Compassionate Use Drug

Slide63of65FromMSSaag,MDatNewOrleans, LA,December4-7,2019,RyanWhiteHIV/AIDSProgramCLINICALCONFERENCE, IAS  USA.